Prostap 3 (Leuprorelin Acetate) DCS 11.25mg Syringe POM x1

Powder and solvent for suspension for injection in pre-filled syringe

Product Description
Contains active ingredient leuprorelin acetate

• Prostap® 3 is a synthetic hormone which can be used to reduce the levels of testosterone and estrogen circulating in the body
• It is used to treat prostate cancer in men and endometriosis in women

Features

Therapeutic indications
• Metastatic prostate cancer.
• Locally advanced prostate cancer, as an alternative to surgical castration.
• As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
• As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• Management of endometriosis, including pain relief and reduction of endometriotic lesions.
• As treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.
• As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.
• In children - treatment of central precocious puberty (girls under 9 years of age, boys under 10 years of age)

Nature and contents of container
• One dual chamber pre-filled syringe containing 11.25 mg leuprorelin acetate powder in the front chamber and 1 ml of Sterile Solvent in the rear chamber.
• 1 x 23 gauge syringe needle fitted with safety device.
• 1 x syringe plunger

Special precautions for storage
• Do not store above 25°C.
• Do not refrigerate or freeze.
S• tore in the original container in order to protect from light.

Shelf life
• Once reconstituted with sterile solvent, the suspension should be administered immediately.

Technical information
• Pack measurements: 33mm x 187mm x 89mm
• Weight: 52g

Product Information Leaflet
https://www.medicines.org.uk/emc/files/pil.4651.pdf